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LETTER TO THE EDITOR
Survival of Inflammatory Breast Cancer Patients
Compared to Non-inflammatory Breast Cancer
Patients in Egypt
To the Editor:
Inflammatory Breast Cancer (IBC) is a rare but
aggressive form of breast cancer that is diagnosed clin-
ically (1). IBC has characteristic clinical and biologic
features suggestive of differences between IBC and
non-IBC. Egypt has about a five times higher propor-
tion of IBC patients than the USA (2–4) with distinct
molecular features of IBC tumors that may reflect a
more aggressive nature of the disease (5,6). Within
Egypt, there have been no past comparisons between
IBC and non-IBC patients with respect to survival.
Therefore, as a part of this study, we decided to com-
pare survival of IBC and non-IBC patients while tak-
ing into account, the epidemiologic, pathologic, and
treatment characteristics of these two groups of
patients from the National Cancer Institute of Cairo
University (NCI-Cairo) in Egypt.
Patients included in this study were diagnosed and
treated at NCI-Cairo from 2000 to 2005. The patients
included two groups, 65 IBC patients and 52 non-IBC
patients. IBC diagnosis was based on the presence of
erythema, edema, and peau d’orange and some of
the patients in this study were included in our
previous studies (5,6). We reviewed the medical
records, pathology reports and radiation records, and
abstracted demographic, clinical and survival informa-
tion (presence of metastases, treatment variables, and
past medical history that is associated with overall
survival). We applied the same exact procedure for
abstracting information from the medical records of
IBC and non-IBC patients. Survival variables included
distant metastases, chemotherapy, radiation dose and
frequency, type of surgical procedure, hormonal ther-
apy, history of hypertension, pulmonary disease, type
II diabetes, other cancers, and presence of chronic
granulomatous mastitis. Duration of disease was the
difference between the date of reported onset of clini-
cal symptoms to the date of death or last date of fol-
low-up of the patient, if lost to follow-up. Survival
status was identified using a standard survey to elicit
information on dead ⁄ alive status, place of death, and
date of last visit to the treating physician. Patients’ rel-
atives provided information on patients who were no
longer living. Trained interviewers who participated in
our previous studies from the Social Work Depart-
ment of NCI-Cairo contacted the patients or next of
kin by phone to elicit the survival information. When
patients or next of kin were not available by phone
because of changed phone numbers or relocation,
home visits were conducted to complete the survival
survey information. Death records were obtained to
validate the date and cause of death. Four patients
were lost to follow-up so death status was unknown.
The study was approved by both Institutional Review
Boards of NCI-Cairo in Egypt and the University of
Michigan.
Statistical analysis was performed using SAS statis-
tical package version 9.1.3 (SAS Inc. Cary, NC) to
obtain adjusted and unadjusted hazard ratios. Cox
proportional hazards were used for analysis of vari-
ables that were significant in the univariate analysis.
These variables included the diagnosis of IBC, lym-
phatic vessel invasion, edema, peau d’orange, ery-
thema, warmth, thickening, pain, itching, distant
metastasis, chemotherapy, radiation, surgery, and hor-
monal therapy. Statistical analysis of the overall sur-
vival for each group (Kaplan–Meier curve for
univariate analysis) was conducted. Comparison of
statistical significance between survival curves was
performed by the log rank Mantel-Cox.
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The mean age of both IBC and non-IBC patients
was 51 years (SD ± 12) with a range of 28–75 years
for IBC patients and 32–79 years for non-IBC
patients. The Kaplan–Meier analysis showed a 2-year
overall survival of 88% for non-IBC patients com-
pared to 80% survival for IBC patients. The 4-year
overall survival rate for non-IBC patients was 67%
compared to 24% for IBC patients (p = 0.02) (Fig. 1).
This study showed that IBC patients had a signifi-
cantly lower overall survival than non-IBC patients at
4 years. Our reported survival of IBC patients from
Egypt at 4 years in this study (24%) is lower than the
trends for overall survival of IBC patients in the USA
in the same decade of 40% at 4 years (7) and 40%
survival at 5 year (8). To our knowledge, this is the
first study to report on the survival of IBC patients in
Egypt where IBC proportions are high and tumors
exhibit distinct molecular pathologic features (2,3,5,6).
However, two studies from Tunisia, where IBC is also
reported at a high proportion, showed a slightly poorer
overall survival at 4–5 years of 19–20% (9,10).
The study has several strengths. First, this is one of
the very few reports on survival difference between
IBC and non-IBC from a developing country. Second,
the availability of detailed information on pathologic,
clinical and treatment data on both groups of patients
added for better understanding of factors influencing
survival. Third, the stable population in Egypt and the
uncommon limited relocation allowed for contacting
the patients and their next of kin to confirm the sur-
vival status, when patients discontinued their follow-
up with the treating physicians. Also, the ability of
our trained team to conduct home visits to track
survival information when patients were not available
by other sources was a significant asset for this study.
The study also has a few limitations. One was the rel-
atively small sample size which may have limited our
ability to estimate the effect of some covariates in the
comparison of survival between the IBC and non-IBC
patients. Another limitation of this study was the
follow-up period of only 4 years for the non-IBC
patients. Also, as we were not able to collect consis-
tent staging data for the patients in the study we did
not add this to the analysis.
In summary, the most important finding of this study
was that IBC patients had a significantly lower overall
survival than non-IBC patients. Future studies should
continue to follow the patients over an extended period
past the 4-years included in this study.
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